Latest phenytoin Stories
- Major milestone for brivaracetam is latest step towards UCB goal of extending treatment choices for adult epilepsy patients with uncontrolled partial-onset seizures BRUSSELS, Jan.
-- Primary efficacy and safety data from the largest Phase 3 brivaracetam study involving 768 patients presented at the 68th Annual Meeting of the American Epilepsy Society BRUSSELS, Dec.
-- Results of Investigational Studies of Perampanel and Rufinamide Accepted as Late-Breaking Posters -- WOODCLIFF LAKE, N.J., Dec. 5, 2014 /PRNewswire/ -- Eisai Inc.
WOODCLIFF LAKE, N.J., Oct. 20, 2014 /PRNewswire/ -- Eisai Inc. announced today that the U.S.
Researchers have identified genetic variants that are associated with severe adverse skin reactions to the antiepileptic drug phenytoin.
- Brivaracetam is the newest investigational medicine to emerge from UCB's rich late-stage pipeline BRUSSELS, July 23, 2014 /PRNewswire/ -- regulated information -- UCB today announced an important
Transparency Market Research added a new report "Global Epilepsy Therapeutics Market: Industry Analysis, Size, Share, Growth and Forecast 2019" to its report store.
WOODCLIFF LAKE, N.J., June 16, 2014 /PRNewswire/ -- Eisai Inc.
According to a recently published research letter from JAMA, the severe cutaneous reactions are typically experienced following use of a broad array of prescription and over-the-counter medications.
WOODCLIFF LAKE, N.J., April 25, 2014 /PRNewswire/ -- Eisai Inc.
- Withering but not falling off, as a blossom that persists on a twig after flowering.